A5048236397- Cannabis and Cannabinoid Research
- Sleep and Wakefulness Research
- Sleep and related disorders
- Neuroendocrine regulation and behavior
- Forensic Toxicology and Drug Analysis
- Stress Responses and Cortisol
- Substance Abuse Treatment and Outcomes
- Psychedelics and Drug Studies
- Prenatal Substance Exposure Effects
- Alcohol Consumption and Health Effects
- Epilepsy research and treatment
- Neurotransmitter Receptor Influence on Behavior
- Bipolar Disorder and Treatment
- Neuroscience of respiration and sleep
- Coffee research and impacts
- Infant Health and Development
- Neuroscience and Neuropharmacology Research
- Circadian rhythm and melatonin
- Pharmacological Effects and Toxicity Studies
- Sexuality, Behavior, and Technology
- Biochemical effects in animals
- Obsessive-Compulsive Spectrum Disorders
- Evolutionary Psychology and Human Behavior
- Child Nutrition and Feeding Issues
- Schizophrenia research and treatment
The University of Sydney
2015-2025
Woolcock Institute of Medical Research
2020-2024
Macquarie University
2023-2024
Objectives To examine the knowledge and attitudes of Australian general practitioners (GP) towards medicinal cannabis, including patient demand, GP perceptions therapeutic effects potential harms, perceived willingness to prescribe. Design, setting participants A cross-sectional survey completed by 640 GPs (response rate=37%) attending multiple-topic educational seminars in five major cities between August November 2017. Main outcome measures Number patients enquiring about GPs, conditions...
In 2016, the Australian federal government passed legislation enabling a range of cannabis-based products to be prescribed patients by registered healthcare professionals. An online survey conducted immediately prior these legislative changes found that vast majority respondents at time were illicitly sourcing cannabis plant matter, smoking was preferred route administration and mental health, chronic pain, sleep conditions most frequently cited reasons for medical use. This manuscript...
Abstract Background Australia has had a framework for legal medicinal cannabis since 2016, yet prior online surveys in 2016 and 2018 indicated that most consumers continued to use illicit medical products. Regulatory data indicate an increase the prescription of 2019, this survey examines consumer experiences prescribed (MC) Australia. Methods A cross-sectional anonymous was administered September 2020 January 2021. Recruitment via social media, professional forums, practices. Participant...
Recent surveys suggest that many parents are using illicit cannabis extracts in the hope of managing seizures their children with epilepsy. In current Australian study we conducted semi-structured interviews families diverse forms epilepsy to explore attitudes towards and experiences extracts. This included or previous users treat child's (n = 41 families), who had never used 24 families). For those cannabis, were analysed for cannabinoid content, specific comparison samples rated by as...
Epilepsy Action Australia conducted an Australian nationwide online survey seeking opinions on and experiences with the use of cannabis-based products for treatment epilepsy. The was promoted via Australia's main website, their Facebook page, by word mouth. consisted 39 questions assessing demographics, clinical factors, including diagnosis seizure types, towards cannabis in A total 976 responses met inclusion criteria. Results show that 15% adults epilepsy 13% parents/guardians children...
Background: Cannabidiol (CBD), a major cannabinoid of Cannabis sativa, is widely consumed in prescription and non-prescription products. While CBD generally considered ‘non-intoxicating’, its effects on safety-sensitive tasks are still under scrutiny. Aim: We investigated the driving performance. Methods: Healthy adults ( n = 17) completed four treatment sessions involving oral administration placebo, or 15, 300 1500 mg randomised, double-blind, crossover design. Simulated performance was...
Cannabis was legalised for medical purposes in 2016. Uptake initially slow, but since 2019 there has been a large increase the number of Australians who have prescribed cannabis reasons. Yet significant consumers continue to treat their conditions via illicitly-sourced cannabis. Little is known about how these two groups differ.
Abstract The neuropeptide oxytocin ( OT ), given acutely, reduces self‐administration of the psychostimulant drug methamphetamine METH ). Additionally, chronic administration to adolescent rats levels alcohol consumption in adulthood, suggesting developmental neuroplasticity system relevant addiction‐related behaviors. Here, we examined whether exposure during adolescence might subsequently inhibit adulthood. Female S prague‐ D awley were administered vehicle or (1 mg/kg, i.p.) once daily...
The neuropeptide oxytocin attenuates reward and abuse for the psychostimulant methamphetamine (METH). Recent findings have implicated nucleus accumbens (NAc) core subthalamic (STh) in modulation of acute METH relapse to METH-seeking behaviour. Surprisingly, receptor (OTR) is only modestly involved both regions attenuation METH-primed reinstatement. Coupled with limited investigation role OTR psychostimulant-induced behaviours, we primarily investigated whether there are cellular changes NAc...
Introduction Insomnia is a highly prevalent and costly condition that associated with increased health risks healthcare utilisation. Anecdotally, cannabis use frequently reported by consumers to promote sleep. However, there limited research on the effects of sleep daytime function in people insomnia disorder using objective measures. This proof-of-concept study will evaluate single dose an oral cannabis-based medicine participants chronic disorder. Methods analysis A randomised, crossover,...
As the use of cannabis for medical purposes becomes increasingly prevalent, driving under influence (DUIC) is emerging as a major public health issue. Understanding current behaviours, attitudes and perceptions around DUIC in users an important first step addressing this Here we present results from driving-related subsection Cannabis Medicine 2018-2019 Survey (CAMS18) Australian (n = 1388). Of 806 respondents who reported motor vehicle last month, 34.6% said they typically drive within 3...
BACKGROUND: Tourette syndrome is characterized by chronic motor and vocal tics. There preliminary evidence of benefit from cannabis products containing Δ9-tetrahydrocannabinol (THC) that coadministration cannabidiol (CBD) improves the side-effect profile safety. METHODS: In this double-blind, crossover trial, participants with severe were randomly assigned to a 6-week treatment period escalating doses an oral oil 5 mg/ml THC CBD, followed course placebo, or vice versa, separated 4-week...
Anorexia nervosa (AN) is an eating disorder (ED) with high mortality rates and limited response to existing treatments, prompting the need identify effective agents adjuncts. There evidence for emerging role neuropeptide oxytocin (OT) in pathophysiology of AN, studies showing a perturbed oxytocinergic system patients AN. Preliminary has demonstrated that intranasal OT (IN-OT) can produce anxiolytic effects as well reducing concern about eating, dysfunctional attentional biases related...
Current treatments for alcohol use disorders (AUD) have limited efficacy. Recently, Cannabidiol (CBD) has been examined in a multitude of clinical settings. Preclinical and results suggest that CBD might be particularly well suited the treatment AUD may reduce cue stress-induced craving seeking. This study aims to investigate this new pharmacotherapy with particular focus on neurobiological physiological indicators craving.
Preclinical studies have demonstrated that cannabidiol (CBD) reduces alcohol-seeking behaviors and may potential for managing alcohol use disorder (AUD). In this study, we examined the effects of CBD versus placebo on (i) psychophysiological, craving anxiety responses to appetitive cues; (ii) tolerability measures including cognitive functioning. Twenty-two non-treatment-seeking individuals with AUD (DSM-5) participated in a cross-over, double-blind, randomized trial, receiving either 800 mg...